Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial

IMPORTANCE: Neovascular age-related macular degeneration is the leading cause of blindness in individuals 50 years or older. The availability of a ranibizumab biosimilar product (SB11) may facilitate access to an effective alternative to this treatment. OBJECTIVE: To demonstrate equivalence of effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Woo, Se Joon, Veith, Miroslav, Hamouz, Jan, Ernest, Jan, Zalewski, Dominik, Studnička, Jan, Vajas, Attila, Papp, Andras, Gabor, Vogt, Luu, James, Matuskova, Veronika, Yoon, Young Hee, Pregun, Tamás, Kim, Taehyung, Shin, Donghoon, Bressler, Neil M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677876/
https://www.ncbi.nlm.nih.gov/pubmed/33211076
http://dx.doi.org/10.1001/jamaophthalmol.2020.5053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677876/
https://www.ncbi.nlm.nih.gov/pubmed/33211076
http://dx.doi.org/10.1001/jamaophthalmol.2020.5053

Ejemplares similares